Alzheimer's drug trial halted early: what happened?

NCT ID NCT06247345

Terminated Disease control Sponsor: Alzheimer's Disease Expert Lab (ADEL), Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tested a new drug, ADEL-Y01, in healthy volunteers and people with mild Alzheimer's or mild cognitive impairment. The goal was to check safety and how the drug moves through the body. The trial was stopped early, so results are limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease brain disorder central nervous system disorder Cognition Disorders cognitive disorder Cognitive Dysfunction dementia nervous system disorder neurodegenerative disease psychiatric disorder tauopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALZHEIMER DISEASE

Contacts and locations

Locations

Accel Research - Neurostudies

Decatur, Georgia, 30030, United States
CenExel ACT

Anaheim, California, 92801, United States
Innovation Medical Research

Palmetto Bay, Florida, 33157, United States
K2 Medical Research - Orlando

Maitland, Florida, 32751, United States
K2 Medical Research - The Villages

Lady Lake, Florida, 32159, United States
Quest Research Institute

Farmington Hills, Michigan, 48334, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.